$MDNC · Medinotec Inc.
Medinotec Inc. filed its Q2 FY2027 10-Q for the period ended August 31, 2026. Revenue was essentially flat at $3.2M (-1.1% YoY), while net income collapsed to $40,866 from $346,566 in the prior-year quarter. Gross margin deteriorated as cost of goods sold rose to $1.64M from $1.25M. The U.S. segment operating loss widened to $349,828 from $213,034, driven by Outflo commercialization spending. Operating cash flow for the first half swung to -$68,599 from +$464,300 a year earlier. Cash on hand declined to $2.58M from $2.76M at fiscal year-end.
- Q2 FY2027 net income fell to $40,866 from $346,566 in Q2 FY2026, an 88% decline.
- Q2 revenue was $3.2M, down 1.1% YoY from $3,236,305.
- Gross margin contracted sharply: Q2 gross profit dropped to $1,559,897 from $1,983,298.
- U.S. segment operating loss widened to $349,828 from $213,034, driven by Outflo commercialization costs.
- Operating cash flow turned negative at -$68,599 for H1 FY2027 vs. +$464,300 in H1 FY2026.
Price data unavailable.
An 88% net income collapse, negative operating cash flow, and widening U.S. losses on a flat revenue base signal deteriorating fundamentals for a micro-cap device company with only $2.58M in cash.
As a small-cap medical device company with two FDA 510(k)-cleared products (Trachealator, Outflo), Medinotec is in the early commercialization phase. The widening U.S. losses are typical for device launches but the pace of cash burn relative to revenue scale is a concern.
South African Rand volatility creates material currency translation risk, with $40,031 in other comprehensive loss from FX translation in H1 FY2027. The U.S. segment remains unprofitable and its losses are widening as Outflo commercialization ramps, with no clear timeline to breakeven.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.